

Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Temozolomide Injection Formulation

Manufacturer or supplier's details

Company : MSD

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000

Emergency telephone number : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS Classification

Acute toxicity (Oral) : Category 3

Serious eye damage/eye irri-

tation

Category 2A

Germ cell mutagenicity : Category 2

Carcinogenicity : Category 2

Reproductive toxicity : Category 1B

Specific target organ toxicity - :

repeated exposure (Oral)

Category 2 (Bone marrow, thymus gland, Lymph nodes,

spleen)

GHS label elements

Hazard pictograms



Signal word : Danger

Hazard statements : H301 Toxic if swallowed.

H319 Causes serious eye irritation.



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

H341 Suspected of causing genetic defects.

H351 Suspected of causing cancer.

H360FD May damage fertility. May damage the unborn child. H373 May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Precautionary statements

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. Rinse mouth.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P308 + P313 IF exposed or concerned: Get medical advice/

P337 + P313 If eye irritation persists: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Citric acid	77-92-9	>= 10 -< 20
Temozolomide	85622-93-1	>= 1 -< 10

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting.

Call a physician or poison control centre immediately.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

delayed

Toxic if swallowed.

Causes serious eye irritation.
Suspected of causing genetic defects.

Suspected of causing cancer.

May damage fertility. May damage the unborn child.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Chlorine compounds

Specific extinguishing meth- : Use extinguishing measures that are appropriate to local cir-



Temozolomide Injection Formulation

Version SDS Number: Date of last issue: 2023/03/20 Revision Date: 27565-00024 9.1 2023/09/26 Date of first issue: 2014/11/03

cumstances and the surrounding environment. ods

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Avoid release to the environment. Environmental precautions

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling Do not get on skin or clothing.

> Do not breathe dust. Do not swallow. Do not get in eves.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation.



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Explosives

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m3 (OEB 5)	Internal
		Wipe limit	1 μg/100 cm2	Internal

Engineering measures : Use closed processing systems or containment technologies

to control at source (e.g., glove boxes/isolators) and to pre-

vent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems

are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the

workplace.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Hazardous decomposition

products

Oxidizing agents

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Toxic if swallowed.



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

Product:

Acute oral toxicity : Acute toxicity estimate: 243.59 mg/kg

Method: Calculation method

Components:

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Temozolomide:

Acute oral toxicity : LD50 (Dog): 19 mg/kg

LD50 (Rat): 315 mg/kg

LD50 (Mouse): 205 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Citric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Citric acid:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Method : OECD Test Guideline 405

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

Components:

Temozolomide:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig Result : negative

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro micronucleus test

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Temozolomide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: Chromosome aberration test in vitro

Test system: Human lymphocytes

Result: positive

Germ cell mutagenicity -

Assessment

Positive results from in vitro mammalian mutagenicity assays,

chemical structure activity relationship to known germ cell

mutagens

Carcinogenicity

Suspected of causing cancer.

Components:

Temozolomide:

Species : Rat
Application Route : Oral
Exposure time : 6 Months

4 mg/kg body weight



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

Result : positive

Target Organs : Mammary gland

Carcinogenicity - Assess-

ment

Limited evidence of carcinogenicity in animal studies

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

Citric acid:

Effects on foetal develop-

ment

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Temozolomide:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: LOAEL: 8.5 mg/kg body weight

Result: positive

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: LOAEL: 13 mg/kg body weight

Result: positive, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertil-

ity, based on animal experiments., Clear evidence of adverse

effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Citric acid:

Assessment : May cause respiratory irritation.

STOT - repeated exposure

May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Components:

Temozolomide:

Exposure routes : Ingestion

Target Organs : Bone marrow, thymus gland, Lymph nodes, spleen
Assessment : Causes damage to organs through prolonged or repeated



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

exposure.

Repeated dose toxicity

Components:

Citric acid:

Species : Rat

NOAEL : 4,000 mg/kg LOAEL : 8,000 mg/kg Application Route : Ingestion Exposure time : 10 Days

Temozolomide:

Species : Rat, female
NOAEL : 4 mg/kg
LOAEL : 21 mg/kg
Application Route : Oral
Exposure time : 6 Months

Target Organs : Lymph nodes, thymus gland, Bone marrow, Reproductive

organs

Species : Rat, male
NOAEL : 8.5 mg/kg
LOAEL : 34 mg/kg
Application Route : Oral
Exposure time : 6 Months

Target Organs : Lymph nodes, thymus gland, Bone marrow, male reproductive

organs, Gastrointestinal tract

Species : Dog
NOAEL : 2.5 mg/kg
LOAEL : 6.3 mg/kg
Application Route : Oral
Exposure time : 6 Months

Target Organs : Bone marrow, spleen, male reproductive organs, Gastrointes-

tinal tract, thymus gland

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Temozolomide:

Ingestion : Symptoms: Blood disorders, Nausea, Vomiting, Diarrhoea,

anorexia, Fatigue, hair loss



Temozolomide Injection Formulation

Version SDS Number: Date of last issue: 2023/03/20 Revision Date: 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Citric acid:

Toxicity to fish LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 1,535 mg/l

Exposure time: 24 h

Temozolomide:

Toxicity to fish LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 90

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 40

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50: > 100 mg/l Toxicity to microorganisms

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

Components:

Citric acid:

Biodegradability Result: Readily biodegradable.

Biodegradation: 97 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Temozolomide:

Result: rapidly degradable Biodegradability

Biodegradation: 83 %



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

Exposure time: 35 d

Stability in water : Degradation half life (DT50): < 1 d

Bioaccumulative potential

Components:

Citric acid:

Partition coefficient: n-

octanol/water

log Pow: -1.72

Temozolomide:

Partition coefficient: n-

octanol/water

log Pow: 1.35

Mobility in soilNo data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

13 / 16



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

Packing instruction (passen: Not applicable

ger aircraft)

IMDG-Code

UN number Not applicable Proper shipping name Not applicable Not applicable Class Not applicable Subsidiary risk Not applicable Packing group Not applicable Labels **EmS Code** Not applicable Marine pollutant Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials

Type of hazardous materials subject to distribution and : Not applicable

control, Annex I

Type of hazardous materials subject to distribution and : Not applicable

control, Annex II

The components of this product are reported in the following inventories:

AICS : not determined



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2023/09/26

Further information

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk, IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for



Temozolomide Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/03/20 9.1 2023/09/26 27565-00024 Date of first issue: 2014/11/03

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN